DeltaNu Whats New in 06

1
DeltaNu Whats New in 06
Keith Carron, CEO Swift Tour Casper, WY
September 13, 2006
2
Teaching --Research
Portable -- Analysis
3
2006 Improving the product line
Advantage Series
Standard 2 mW HeNe laser Now 100 mW _at_ 532 nm,
120 mW _at_ 785 nm, 200 mW _at_ 808 nm.
Inspector Series
Standard 75 mW 785 nm Now 120 mW at 785 nm
with an externally coupled stabilizer. This
makes product to product reproducibility
extremely high. It enables library technology.
4
Adding Value to Existing Products
5
Oscar for Inventors
RockHound
Something New Out of Something Old

• This year
• Getty Museum Purchased
• Detroit Art Institute (Ordered)
• Instrumentación Específica de Materiales
  (Order in process)
• New York Metropolitan (Requested)
• University of Arizona 1000 Mineral Library.

DeltaNu at the Louvre
6
Pull of New Markets -- Pushing New Technology
Brand Security Counterfeiting Homeland
Security Point-of-Care
ReporteR
Cell Phone Technology Compact Memory Optical
Information Storage Photonic Crystals
7
-- Taking Raman to the Limit
Main Entry transducer   Function noun a
device that is actuated by power from one system
and supplies power usually in another form to a
second system lta loudspeaker is a transducer that
transforms electrical signals into sound energygt
8
Brand Security
Proprietary Raman Ink
How does it work?
Material Identification through Raman
spectroscopy.
Libraries of Raman Barcodes
Anti-counterfeiting
Wavenumbers
9
2006 -- Taking advantage of our uniqueness
Free-space DeltaNu module
785 nm or 532 nm
10
High-end Research Grade Raman Microscope
Released this year The ExamineR uses our unique
free-space design. Competitors place a
microscope on their Raman systems we place our
Raman system on a microscope. This produces
greatly smaller footprints and very high
sensitivity.
11
1.0 DeltaNu LLC, LARAMIE, WINS DARPA PHASE II
                                Congratu
lations to DeltaNu in Laramie on their recent
DARPA Phase II award! Project Title Miniature
Long-Range Stand-off ImagingRaman System for
Detection of Biological Materials Principle
Principle Investigator Keith CarronEmail
keith_at_deltanu.comAward 750,000Non-Technical
Summary An urgent national defense need is the
ability to detect WMD chemical and biological
agents and improvised explosive devices (IED) at
a distance with high sensitivity and specificity.
The goal of this DARPA Phase II STTR project is
the development of a prototype hand-held
telescopic Raman spectroscopy system capable of
sensitive, high-specificity, stand-off
identification of chemical (including IED
explosives)and biological materials at distances
of up to one kilometer, dependent upon "seeing"
conditions. Among the issues addressed by this
development are signal interferences from
sunlight, fluorescence and other out-of-phase
sources of noise. Eye safety issues are also
addressed. This development will lead to a number
of commercialization opportunities, especially in
multiplexed bio-assay and hazmat chemical
identification at long distances. Additional
information about DeltaNu can be found on their
web site www.deltanu.com
Crescent Diagnostics and DeltaNu Ink IP
Agreement   July 18th - Limerick, Ireland and
Laramie, Wyoming USA   Crescent Diagnostics Ltd.
has signed an intellectual property option
agreement with DeltaNu LLC. This agreement gives
Crescent an exclusive option to develop and
market products from intellectual property that
was invented at the University of Limerick and
the University of Wyoming and is jointly held by
Crescent and DeltaNu. The intellectual property
describes a novel way to use Raman spectroscopy
to diagnose bone health conditions like
osteoporosis. The terms of the agreement were not
disclosed.   "We are very happy to conclude an
agreement like this - it formalizes a great
working relationship we've had with DeltaNu for
the past two years," says Ernest Poku, CEO of
Crescent Diagnostics.   "The applications for
Raman spectroscopy are growing," says Dr. Keith
Carron, CEO of DeltaNu, "and DeltaNu is fortunate
to partner with a leader like Crescent as it
brings this important technology to the
market."   About Crescent Diagnostics
Ltd   Crescent Diagnostics Ltd was established
in 2004 to develop and commercialize a bone
quality test based on Raman technology. Crescent
Diagnostics conducts research at its offices in
Limerick, Ireland and maintains a corporate
office in London, UK. The company is runby an
experience medical diagnostics management team.
For more information about Crescent Diagnostics,
please visit the website at www.crescentds.com.  
12
Hypothesis Osteoporosis is a disease of bone
protein and bone protein health is exhibited
through fingernails
CH2
CH2 Bending
S-S
3
4
3
S-S
2
2
1
1
500
1000
1500
2000
500
1000
1500
2000
Wavenumbers
(I(2) I(1)/I(4) I(3)
0.25
136 O 160 O 202 H 216 H
0.2
0.15
0.1
0.05
0
216
136
160
202
Patient
13
2006 -- Thinking Big DeltaNu is on 6 Continents
14
Tony Nevshemal, COO Rebekah Peifer, Office
Manger Shane Buller, Senior Engineer Katie
Keeney, Office Assistant Branden Phillips,
Production Manager Keith Carron, CEO Rick Cox, VP
Sales and Marketing
Not Pictured Minden Shuster, Marketing
Associate Matt Russell, Mechanical Engineer
Travis Thompson, Applications Scientist
Gene Watson, Business Advisor George Lucy,
Production Associate Mark Watson, Design
Engineer Phillip Duran, Production Assistant
Wyoming Graduates
15
Acknowledgements
SBIR Over 4,000,000 in startup funds National
Science Foundation National Institutes of
Health Department of Energy United States
Department of Agriculture DARPA WSSI Phase 0
Wyoming Business Council Wyoming Trade
Show Incentive Grant Work-Force Development
Assistance CDBG Assistance with
Facility WTBC University of Wyoming SBDC Manufactu
ring Works Research Product Center